

# Chapter 1

## Overview of Clinical Trial and Pharmacovigilance Process and Areas of Application of Computer System

**Sowmyanarayan Srinivasan**  
*Accenture Services Pvt Ltd, India*

### **ABSTRACT**

*The overall process of getting a drug to the market is a long one and takes 10-15 years and costing close to a billion dollar. The success rate as the compound travels from the initial discovery phase to clinical and then through to the market is about 1 in 10,000. The two key phases which together contribute the most to the cost and timeline are clinical development and pharmacovigilance. These two phases together also account for the maximum number of failures. In this chapter, we will look in detail at these two phases with a focus on the business process and process areas which have application of computer systems. The chapter will focus on looking at the various phases of clinical development and their endpoints. Clinical development is the process of testing a drug for safety and efficacy in human subjects. Clinical trial is conducted in 3 phases with the 4th phase which is ongoing post approval which forms an important part of the pharmacovigilance process. These phases will be elaborated in detail.*

### **INTRODUCTION AND BACKGROUND**

The overall process of getting a drug to the market is a long one and takes 10-15 years and costing close to a billion dollar. The success rate as the compound travels from the initial discovery phase to clinical and then through to the market is about 1 in 10,000. The two key phases which together contribute the most to the cost and timeline are clinical development and pharmacovigilance. These two phases together also account for the maximum number of failures. In this chapter, we will look in detail at these two phases with a focus on the business process and process areas which have application of computer systems.

DOI: 10.4018/978-1-5225-1762-7.ch001

Figure 1 illustrates the value chain of bringing a drug to the market starting from understanding of disease to commercialization of the drug for the disease. (R&D Pipeline Management, University of Wisconsin, n.d)

The entire process of drug discovery and development starts *in silico* (in the computer), moves to *in vitro* (in the laboratories) and then finally *in vivo* (inside living beings like animals and humans). This is keeping with the spirit of ensuring safety to all living beings. As the molecule progresses to becoming a drug it graduates from computer to laboratory to living beings.

The initial phase of drug discovery is focused on understanding the disease better and potential drug targets that are relevant for the disease which is largely driven by biology. This part primarily focuses on:

- Understanding the mechanism of diseases;
- Identifying potential targets for therapeutic intervention;
- Evaluating potential drug candidates.

Once the disease is better understood and potential targets identified, the next phase focuses on various aspects of the molecule that can become potential drugs and is largely driven by chemistry. This part addresses the following needs:

- Inventing or identifying safe & effective chemical entities that will become potential drug candidates.
- These drug candidates will act as leads to act on the target disease


These two initial phases of biology and chemistry are largely *in silico* and *in vitro*.

One of the key qualifying parameter for a molecule to become a drug is its medicinal properties. This science is called medicinal chemistry and this characterizes the molecule before it is used in any living being.

Medicinal chemistry is a scientific discipline involved with designing, synthesizing and developing pharmaceutical drugs.

Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and

Figure 1.



11 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:  
[www.igi-global.com/chapter/overview-of-clinical-trial-and-pharmacovigilance-process-and-areas-of-application-of-computer-system/174118](http://www.igi-global.com/chapter/overview-of-clinical-trial-and-pharmacovigilance-process-and-areas-of-application-of-computer-system/174118)

## Related Content

---

### Colonic Bacterial Enzymes: Pharmaceutical Significance and Applications

Srushti M. Tambe and Namita D. Desai (2018). *Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology* (pp. 71-99).

[www.irma-international.org/chapter/colonic-bacterial-enzymes/203811](http://www.irma-international.org/chapter/colonic-bacterial-enzymes/203811)

### Molecular Dynamics Simulations for Biological Systems

Prerna Priya, Minu Kesheri, Rajeshwar P. Sinha and Swarna Kanchan (2017). *Pharmaceutical Sciences: Breakthroughs in Research and Practice* (pp. 1044-1071).

[www.irma-international.org/chapter/molecular-dynamics-simulations-for-biological-systems/174160](http://www.irma-international.org/chapter/molecular-dynamics-simulations-for-biological-systems/174160)

### Molecular Modelling, Dynamics, and Docking of Membrane Proteins: Still a Challenge

Nanda Kumar Yellapu (2017). *Pharmaceutical Sciences: Breakthroughs in Research and Practice* (pp. 747-769).

[www.irma-international.org/chapter/molecular-modelling-dynamics-and-docking-of-membrane-proteins/174149](http://www.irma-international.org/chapter/molecular-modelling-dynamics-and-docking-of-membrane-proteins/174149)

### Medicinal Plant Treatments for Peptic Ulcers: Applications and Future Perspectives

G. Nivetha, Sneha Unnikrishnan and Karthikeyan Ramalingam (2023). *Pharmacological Benefits of Natural Agents* (pp. 172-199).

[www.irma-international.org/chapter/medicinal-plant-treatments-for-peptic-ulcers/327309](http://www.irma-international.org/chapter/medicinal-plant-treatments-for-peptic-ulcers/327309)

### Methods for Docking and Drug Designing

Ahmad Abu Turab Naqvi and Md. Imtaiyaz Hassan (2016). *Methods and Algorithms for Molecular Docking-Based Drug Design and Discovery* (pp. 39-53).

[www.irma-international.org/chapter/methods-for-docking-and-drug-designing/151882](http://www.irma-international.org/chapter/methods-for-docking-and-drug-designing/151882)